Femasys (FEMY) CFO receives 34,122 Series D-1 warrants at $0.58

Rhea-AI Filing Summary

Femasys Inc.’s Chief Financial Officer, Dov Elefant, received a grant of 34,122 Series D-1 Warrants on March 19, 2026. The warrants are exercisable into 34,122 shares of common stock at an initial exercise price of $0.58 per share and expire on March 19, 2036.

The award was issued in a private placement as consideration under an Omnibus Amendment and Consent Agreement. Exercise of these warrants is subject to certain limitations under Nasdaq Capital Market rules, which may restrict when and how fully they can be exercised.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Elefant Dov

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Series D-1 Warrants	34,122	$0.00	--

Holdings After Transaction: Series D-1 Warrants — 34,122 shares (Direct)

Footnotes (1)

1. Holder may, at its option, exercise the Series D-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.58 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series D-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market. The reported securities were issued to the reporting person in a private placement as consideration in connection with that certain Omnibus Amendment and Consent Agreement, dated as of March 19, 2026 by and among the Company, the reporting person and the other parties thereto.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Elefant Dov

(Last) (First) (Middle)

C/O FEMASYS INC.

3950 JOHNS CREEK COURT, SUITE 100

(Street)

SUWANEE GEORGIA 30024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FEMASYS INC [ FEMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series D-1 Warrants	$0.58(1)	03/19/2026		A		34,122		03/19/2026	03/19/2036	Common stock, par value $0.001 per share	34,122(2)	(3)	34,122	D

Explanation of Responses:

1. Holder may, at its option, exercise the Series D-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.58 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series D-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

2. The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

3. The reported securities were issued to the reporting person in a private placement as consideration in connection with that certain Omnibus Amendment and Consent Agreement, dated as of March 19, 2026 by and among the Company, the reporting person and the other parties thereto.

	/s/ Kathy Lee-Sepsick, Attorney-in-fact	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Femasys (FEMY) disclose about its CFO in this Form 4?

Femasys reported that its Chief Financial Officer, Dov Elefant, received 34,122 Series D-1 Warrants on March 19, 2026. These derivative securities can be exercised into the company’s common stock at a fixed price, adding to his incentive-based compensation exposure.

How many Series D-1 Warrants did the Femasys CFO receive and at what price?

The Femasys CFO received 34,122 Series D-1 Warrants with an initial exercise price of $0.58 per share. Each warrant is exercisable into one share of common stock, creating potential future ownership if exercised under the specified terms and market conditions.

When do the Femasys CFO’s Series D-1 Warrants expire?

The Series D-1 Warrants granted to the Femasys CFO expire on March 19, 2036. This long-dated expiration gives a multi-year window during which the warrants may be exercised, subject to the warrant terms and Nasdaq Capital Market limitations described in the disclosure.

Why were the Series D-1 Warrants issued to the Femasys CFO?

The reported securities were issued to the Femasys CFO in a private placement as consideration under an Omnibus Amendment and Consent Agreement dated March 19, 2026. This links the warrant grant to a contractual arrangement involving the company and other parties.

Are there any limits on exercising the Femasys CFO’s Series D-1 Warrants?

Yes. The disclosure states the CFO’s ability to exercise the Series D-1 Warrants for common shares is subject to certain limitations under Nasdaq Capital Market rules. These limitations can restrict the extent or timing of warrant exercises, affecting when shares may be obtained.

What type of transaction is reported in the Femasys (FEMY) Form 4 for the CFO?

The filing shows a derivative transaction coded “A,” described as a grant, award, or other acquisition. It reflects the CFO acquiring 34,122 Series D-1 Warrants, not an open-market stock purchase or sale, and involves no stated cash payment at the time of the grant.